Annual medical and indirect costs of various diseases in the United States.
Source: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Appendix C. The Economic Cost of Pain in the US. Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education. Washington (DC): National Academies Press (US); 2011
Further development will focus on carrying out as quickly and efficiently as possible the necessary preclinical studies to evaluate safety and toxicology, as well as producing clinical trial material with the aim of obtaining the approval of a regulatory authority to conduct the first human clinical trials with COZY01.
A prototype of the AAV vector that acts as a carrier of the genetic material in gene therapy has been developed by Zyneyro and tested in a preclinical pain model with very good and long-lasting effect. The upcoming work is focused on optimizing the genetic material to be included in the vector.
CombiGene is currently conducting two gene therapeutic development projects: one for treatment of epilepsy that cannot otherwise be treated with drugs and one for treatment of lipodystrophy, a rare condition characterized by an abnormal distribution of fatty tissue in the body.
CombiGene now has a well-established international network within both the pharmaceutical industry and academia. The ambition is to form strategic partnerships for continued development and commercialization of the two projects which CombiGene is currently pursuing and to identify potential new projects in areas in which it may be possible to apply gene therapy.
CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282
CombiGene´s project CGT2 is supported by the Eurostars Programme. Project ID: 114714
Within the framework of the epilepsy project CG01, CombiGene has been collaborating with Lund University and the University of Copenhagen for many years. In recent years, CombiGene has also established collaboration regarding the preclinical development of the lipodystrophy project CGT2 with Stockholm University, University Medical Center Hamburg-Eppendorf and University of Michigan Medical School.